Group 1 - The company Shanxi Qianyuan Pharmaceutical Group Co., Ltd. announced a pre-disclosure of share reduction by several directors and senior management [1] - The total shares planned to be reduced by the five individuals amount to no more than 426,600 shares, representing 0.1718% of the company's total share capital [1] - The individuals involved in the reduction include Yu Junxian, Gu Baoping, Yu Yingmin, He Yanjie, and Luo Kairui, with specific shareholdings and planned reductions detailed [1][2] Group 2 - The reasons for the share reduction include tax payments related to equity incentives and personal funding needs [2] - The shares to be reduced are sourced from various holdings, including pre-IPO shares, capital reserve conversions, and equity incentive grants [2] - The reduction price will be determined based on market conditions at the time of the sale, indicating some uncertainty in the execution of the plan [3] Group 3 - The share reduction plan does not violate any relevant laws or regulations and will not lead to changes in the company's control or governance structure [3] - The company will continue to monitor the progress of the share reduction plan and fulfill its information disclosure obligations as required [3]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that several executives plan to reduce their holdings in the company within three months after a 15 trading day period from the announcement date [1] Summary by Relevant Categories Shareholding Reduction - Executive Yu Junxian plans to reduce holdings by up to 289,200 shares, accounting for 0.1165% of the total share capital of the company [1] - Executive Gu Baoping plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive Yu Yingmin plans to reduce holdings by up to 43,700 shares, accounting for 0.0176% of the total share capital of the company [1] - Executive He Yanjie plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1] - Executive Luo Kairui plans to reduce holdings by up to 25,000 shares, accounting for 0.0101% of the total share capital of the company [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-061 山西仟源医药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 分别持有本公司股份 1,336,800 股(占公司总股本 0.5383%)、325,173 股（占 公司总股本 0.1309%）、325,173 股（占公司总股本 0.1309%）、250,000 股（占公 司总股本 0.1007%）、250,000 股（占公司总股本 0.1007%）的董事、高级管理人 员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生和罗开瑞先 生计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式、大宗交 易的方式减持其持有的公司股份不超过 289,200 股（占公司总股本的 0.1165%）、 山西仟源医药集团股份有限公司（以下简称"公司"）于近日收到董事、高 级管理人员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生、 罗开瑞先生出具的《关于股份减持计划的告知函》，现将相关情况公告如下： | 一、股东的基本情况 | | --- | | 股东 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-061 山西仟源医药集团股份有限公司 关于董事、高级管理人员减持股份的预披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于近日收到董事、高 级管理人员俞俊贤先生、高级管理人员顾宝平先生、虞英民先生、贺延捷先生、 罗开瑞先生出具的《关于股份减持计划的告知函》，现将相关情况公告如下： | 股东姓名 | 任职情况 | 持股数量（股） | 占公司总股本比例（%） | | --- | --- | --- | --- | | 俞俊贤 | 董事、副总裁、 董事会秘书 | 1,336,800 | 0.5383 | | 顾宝平 | 副总裁 | 325,173 | 0.1309 | | 虞英民 | 总工程师 | 325,173 | 0.1309 | | 贺延捷 | 财务总监 | 250,000 | 0.1007 | | 罗开瑞 | 副总裁 | 250,000 | 0.1007 | 一、股东的基本情况 二、本次减持计划的主要内容 1、拟减持原因： 股权激励缴纳税 ...

Group 1 - The company announced that several executives, including the Vice President and other senior management, plan to reduce their holdings in the company within three months after a 15 trading day period from the disclosure date [1] - The total number of shares to be reduced is up to 426,600 shares, which represents 0.1718% of the company's total share capital [1] - Individual reductions include 289,200 shares by Yu Junxian, 43,700 shares by Gu Baoping, 43,700 shares by Yu Yingmin, 25,000 shares by He Yanjie, and 25,000 shares by Luo Kairui, reflecting varying percentages of the total share capital [1]

Market Expansion - As of June 2025, the company's smoking cessation drug, varenicline tartrate tablets, has entered over 100,000 retail stores in the OTC market, with a target of exceeding 140,000 stores by the end of 2025 and 250,000 stores by the end of 2026 [2][3] Market Capacity - The smoking cessation drug market in China has a significant potential, with over 300 million smokers, and the company aims to cover 50 million smokers over the next 10 years [2] User Demographics - The user demographic for varenicline tartrate tablets spans all age groups, with the highest proportion being male smokers in their 30s [3] Cost of Treatment - The estimated cost for each smoker using the varenicline tartrate tablets for a 3-month treatment course is no more than RMB 2,000 [3] Shareholding and Future Plans - The company acknowledges that its major shareholders have a relatively low holding percentage and plans to promote a stock issuance project to specific investors [3]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) reported its semi-annual results for 2025, highlighting an increase in institutional investor holdings and the presence of public funds [1] Group 1: Institutional Investors - As of August 26, 2025, three institutional investors disclosed holdings in QianYuan Pharmaceutical A-shares, totaling 7.2738 million shares, which represents 2.93% of the company's total share capital [1] - The institutional investors include Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No. 1 Private Securities Investment Fund, Shandong Sanzu Private Securities Investment Fund Management Co., Ltd. - Sanzu Sky No. 5 Private Securities Investment Fund, and MORGAN STANLEY & CO. INTERNATIONAL PLC [1] - Compared to the previous quarter, the total institutional holding percentage increased by 0.61 percentage points [1] Group 2: Public Funds - During this reporting period, one public fund was disclosed, which is the ICBC Aggregate Mixed A Fund, unchanged from the previous quarter [1]

Group 1 - The stock price of Qianyuan Pharmaceutical on August 26 was 11.51 yuan, down 0.54 yuan or 4.48% from the previous trading day [1] - The company operates in the chemical pharmaceutical sector, focusing on the research, production, and sales of pharmaceuticals and health foods, as well as medical diagnostics and genetic preservation services [1] - In the first half of 2025, the company reported revenue of 373 million yuan, a year-on-year decrease of 7.01%, and a net profit attributable to shareholders of 380,900 yuan, down 98.86% year-on-year [1] Group 2 - The company's net loss from non-recurring items was 5.01 million yuan, primarily due to the impact of a subsidiary's payment of corporate income tax and late fees [1] - On August 26, the net outflow of main funds for Qianyuan Pharmaceutical was 57.33 million yuan, accounting for 2.19% of the circulating market value [1] - Over the past five days, the net outflow of main funds totaled 128.93 million yuan, representing 4.93% of the circulating market value [1]

国浩律师（上海）事务所 关于 山西仟源医药集团股份有限公司 2025 年第四次临时股东会 之 法律意见书 国浩律师（上海）事务所 关于山西仟源医药集团股份有限公司 2025 年第四次临时股东会 之 法律意见书 致：山西仟源医药集团股份有限公司 作为具有从事中国法律业务资格的律师事务所，国浩律师（上海）事务所（以 下简称"本所"）接受山西仟源医药集团股份有限公司（以下简称"公司"）的委托， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）等法律法规及规范性文件的规定，指派本所 律师出席公司2025年第四次临时股东会（以下简称"本次股东会"），并就本次股 东会的召集、召开程序及表决程序、表决结果等事项出具本法律意见书。 1 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 523 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-059 山西仟源医药集团股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会未涉及变更以往股东会决议的情形。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议召开时间为：2025年8月26日（星期二）下午3:00 5、主持人：副董事长钟海荣先生 6、会议出席情况： （1）股东出席的总体情况： 通过网络投票的股东 213 人，代表股份 2,220,400 股，占公司有表决权股份 总数的 0.8942％。 （2）中小股东出席的总体情况： （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体 时间为 2025 年 8 月 26 日 9:15-9：25，9：30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为 2025 年 8 月 26 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：上海市徐汇区龙耀 ...